Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic, Imanis Life Sciences and the University of Miami.
The Company has exclusive licenses to technologies discovered and validated in the Department of Molecular Medicine that Vyriad CEO Dr. Stephen Russell founded at Mayo Clinic, along with its comprehensive oncolytic virotherapy program. Other significant contributions were made by pioneering researcher in innate immunity and virotherapies, Dr. Glen Barber, in the Department of Cell Biology at the University of Miami Miller School of Medicine, Florida.
Based in Rochester, Minn., Vyriad is a part of Medical Alley, which provides access to expertise and resources to help advance new technologies that improve the lives of patients and inspire hope.
